Heron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Heron Therapeutics

14/08/2023 22:02

* Heron Therapeutics Inc  HRTX.OQ  reported a quarterly
adjusted
loss of 35 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 23 cents per share.
    * Revenue rose 15% to $31.76 million from a year ago;
analysts
expected $31.70 million. 
    * Heron Therapeutics Inc's reported EPS for the quarter was
a loss
of 35 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Heron Therapeutics Inc shares had risen by 39.7% this
quarter and lost 35.2% so far this year.
    * The company reported a quarterly loss of $42.06 million.
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.23          -0.35          Missed
 Mar. 31 2023      -0.20          -0.27          Missed
 Dec. 31 2022      -0.28          -0.17          Beat
 Sep. 30 2022      -0.38          -0.38          Met